The dormancy dilemma: Quiescence versus balanced proliferation

Cancer Research

Volumn 73, Issue 13, 2013, Pages 3811-3816

  Wells, Alan ^a,b   Griffith, Linda ^d   Wells, Jakob Z ^c   Taylor, Donald P ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

^c Taylor Allderdice High School   (United States)

^d Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; COMPUTER SIMULATION; DISEASE MODEL; HUMAN; IN VIVO STUDY; METASTASIS; METASTATIC DORMANCY; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; TUMOR SEEDING;

ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; TUMOR CELLS, CULTURED;

EID: 84880054971     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0356     Document Type: Review

References (43)

1. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7: 834-46.
2. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147: 89-104.
3. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38{alpha}/{beta} signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011;17: 5850-7.
4. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011;108: 12396-400.
5. Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997;137: 767-77.
6. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005;16: 1449-57.
7. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res 2007;9: e208.
8. Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 2011;21: 42-9.
9. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011;7: e1002240.
10. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995;14: 279-301.
11. Kienast Y, vonBaumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16: 116-22.
12. Naumov GN, MacDonald IC, Weinmesiter PM, Kerkvliet N, Nadkarni KV, Wilson SM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002;62: 2162-8.
13. Taylor DP, Wells JZ, Savol A, Chennubhotla C, Wells A. Modeling boundary conditions for balanced proliferation in metastatic latency. Clin Cancer Res 2013;19: 1063-70.
14. Haeno H, Michor F. The evolution of tumor metastases during clonal expansion. J Theor Biol 2010;263: 30-44.
15. Haustein V, Schumacher U. A dynamic model for tumour growth and metastasis formation. J Clin Bioinforma 2012;2: e11.
16. Willis L, Alarcon T, Elia G, Jones JL, Wright NA, Tomlinson IP, et al. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 2010;70: 4310-7.
17. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-64.
18. Naumov GN, Folkman J, Straume O, Aksien LA. Tumor-vascular interactions and tumor dormancy. APMIS 2008;116: 569-85.
19. Chatterjee M, vanGolen KL. Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype. Int J Cancer 2011; 129: 61-9.
20. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med 2011;208: 2641-65.
21. Marshall J-CA, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, et al. Effects of inhibition of the lysophosphatidic acid receptor on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 2012;104: 1306-19.
22. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express Ecadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010;9: e179.
23. Yates C, Shepard CR, Papworth G, Dash A, Beer Stolz D, Tannenbaum S, et al. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res 2007;96: 225-46.
24. Yates CC, Shepard CR, Stolz DB, Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. BR J Cancer 2007;96: 1246-52.
25. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012;150: 764-79.
26. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69: 1279-83.
27. Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, et al. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 2007;99: 309-21.
28. Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 2008;172: 809-17.
29. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85: 1419-24.
30. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, et al. The interplat of HER2/HER3/PI3K and EGFR/HER2/PLC-g1 signalling in breast cancer cell migration and dissemination. J Pathol 2012;227: 234-44.
31. Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, et al. Elevated expression of E-cadherin and alpha-, beta-, and gammacatenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 2004;35: 1469-76.
32. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinoma of the breast and its distant metastases. Breast Cancer Res 2003;5: R217-22.
33. Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron 2012;5: 19-28.
34. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69: 836-44.
35. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 2009;69: 5664-72.
36. Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre-Ghiso JA, et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One 2012;7: e35569.
37. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A 1990; 87: 6698-702.
38. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010; 16: 1414-20.
39. Chao Y,WuQ, Shepard C, Wells A. Hepatocyte-induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis 2012;29: 39-50.
40. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 2010;12: 748-54.
41. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153: 865-73.
42. Wyckoff JB, Jones JG, Condeelis JS, Segall JE. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 2000;60: 2504-11.
43. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006;7: 211-24.